Kalaris Therapeutics (KLRS) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 62.6% versus a loss of 81.7%. Kalaris Therapeutics is the larger company by market cap ($30.5 million vs $21.4 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRS | MGX |
|---|---|---|
| Share price | $1.28 | $0.565 |
| Market cap | $30.47M | $21.36M |
| 1-day change | -5.19% | -7.95% |
| YTD return | -84.83% | -65.12% |
| 1-year return | -81.74% | -62.58% |
| 5-year return | -99.70% | — |
| EPS (TTM) | $-1.84 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $25.21M |
| Revenue growth (YoY) | — | -51.79% |
| Net income (latest FY) | $-43.44M | $-87.87M |
| Operating margin | — | -380.85% |
| Net margin | — | -348.54% |
| 52-week high | $11.88 | $1.87 |
| 52-week low | $1.25 | $0.562 |
| Distance from 52-week high | -89.23% | -69.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1361.72% | +1138.94% |
| Average volume | 77.37K | 163.21K |
| Shares outstanding | 23.80M | 37.81M |
| Employees | 20 | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed KLRS by 19.2 percentage points over the past year.
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
KLRS vs MGX FAQ
Which is bigger, Kalaris Therapeutics or Metagenomi Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $30.47M compared with $21.36M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, KLRS or MGX?
MGX returned -62.58% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Kalaris Therapeutics and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.